Novo Nordisk A/S
BISPECIFIC ANTIBODIES

Last updated:

Abstract:

The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.

Status:
Application
Type:

Utility

Filling date:

14 Oct 2021

Issue date:

3 Mar 2022